GSK deals cell therapy another setback
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
No regrets as Lyell prepares for its first clinical trial
The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Biotech listings shows few signs of cooling
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.